Literature DB >> 17209145

A practical screening tool for anxiety and depression in patients with chronic breathing disorders.

Mark E Kunik1, Pierre N Azzam, Julianne Souchek, Jeffrey A Cully, Nelda P Wray, Laura L Krishnan, Harlan A Nelson, Melinda A Stanley.   

Abstract

Obstructive lung diseases are associated with high rates of depression and anxiety, yet many patients are never screened or treated. This study evaluated the five-question Depression and Anxiety modules of the Primary Care Evaluation of Mental Disorders (PRIME-MD) Patient Questionnaire as a telephone screen in 1,632 patients with chronic breathing disorders at a Veterans Affairs Medical Center in Houston, TX. Subsequent testing of 828 patients with the Beck Depression Inventory-II and the Beck Anxiety Inventory showed that the sensitivity and specificity, respectively, of the Depression and Anxiety modules of the PRIME-MD Patient Questionnaire screening were 94.6% and 49.5% (Depression); 93.7% and 32.2% (Anxiety); and 97.7%, and 36.0% (combined screen), with an overall accuracy of 80.7%. In such populations, these two modules of the PRIME-MD Patient Questionnaire may be a useful screening tool.

Entities:  

Mesh:

Year:  2007        PMID: 17209145     DOI: 10.1176/appi.psy.48.1.16

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  14 in total

Review 1.  Overcoming gaps in the management of chronic obstructive pulmonary disease in older patients: new insights.

Authors:  Jacob Gelberg; R Andrew McIvor
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

2.  Delivery of Brief Cognitive Behavioral Therapy for Medically Ill Patients in Primary Care: A Pragmatic Randomized Clinical Trial.

Authors:  Jeffrey A Cully; Melinda A Stanley; Nancy J Petersen; Natalie E Hundt; Michael R Kauth; Aanand D Naik; Kristen Sorocco; Shubhada Sansgiry; Darrell Zeno; Mark E Kunik
Journal:  J Gen Intern Med       Date:  2017-06-20       Impact factor: 5.128

3.  Identification of Anxiety Symptom Clusters in Patients with COPD: Implications for Assessment and Treatment.

Authors:  Jessica Y Breland; Natalie E Hundt; Terri L Barrera; Joseph Mignogna; Nancy J Petersen; Melinda A Stanley; Jeffery A Cully
Journal:  Int J Behav Med       Date:  2015-10

4.  Caring for the older person with chronic obstructive pulmonary disease.

Authors:  Terri R Fried; Carlos A Vaz Fragoso; Michael W Rabow
Journal:  JAMA       Date:  2012-09-26       Impact factor: 56.272

5.  Cognitive-behavioral therapy for chronic cardiopulmonary conditions: preliminary outcomes from an open trial.

Authors:  Jeffrey A Cully; Melinda A Stanley; Anita Deswal; Nicola A Hanania; Laura L Phillips; Mark E Kunik
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

6.  Screening for depression in chronic obstructive pulmonary disease.

Authors:  Laura J Julian; Steven E Gregorich; Gillian Earnest; Mark D Eisner; Hubert Chen; Paul D Blanc; Ed H Yelin; Patricia P Katz
Journal:  COPD       Date:  2009-12       Impact factor: 2.409

7.  Telephone-administered cognitive behavioral therapy: a case study of anxiety and depression in Parkinson's disease.

Authors:  Connie Veazey; Karon F Cook; Melinda Stanley; Eugene C Lai; Mark E Kunik
Journal:  J Clin Psychol Med Settings       Date:  2009-04-29

Review 8.  Anxiety and depression in COPD: current understanding, unanswered questions, and research needs.

Authors:  Janet Maurer; Venkata Rebbapragada; Soo Borson; Roger Goldstein; Mark E Kunik; Abebaw M Yohannes; Nicola A Hanania
Journal:  Chest       Date:  2008-10       Impact factor: 9.410

Review 9.  Psychiatric aspects of chronic lung disease.

Authors:  Abhishek Jain; Sermsak Lolak
Journal:  Curr Psychiatry Rep       Date:  2009-06       Impact factor: 5.285

10.  Comparison of self-report measures for identifying late-life generalized anxiety in primary care.

Authors:  Sarah A Webb; Gretchen Diefenbach; Paula Wagener; Diane M Novy; Mark Kunik; Howard M Rhoades; Melinda A Stanley
Journal:  J Geriatr Psychiatry Neurol       Date:  2008-12       Impact factor: 2.680

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.